Estela Moreno-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Estela Moreno-García has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Garcia-Vidal
Department of Infectious Diseases, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain
6 shared publications Alex Soriano
Infectious Diseases Department, Hospital Clinic de Barcelona, Barcelona, Spain
5 shared publicationsCelia Cardozo
Infectious Diseases Department, Hospital Clinic de Barcelona, Barcelona, Spain
5 shared publicationsMariana Chumbita
AIDS and HIV infection, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain
5 shared publicationsPedro Puerta-Alcalde
Infectious Diseases Department, Hospital Clinic de Barcelona, Barcelona, Spain
5 shared publications- Carlos Dueñas
Hospital Clínico de Valladolid Valladolid Spain
4 shared publications
Latest Publications
- 12 November 2026
- Published by Wiley in HIV Medicine
Immune outcomes with dolutegravir‐based dual therapy versus bictegravir‐based triple therapy: A multinomial propensity score analysis
Objectives: To compare immune outcomes after switching to dolutegravir/lamivudine (DTG/3TC), dolutegravir/rilpivirine (DTG/RPV) and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). Methods: Three Spanish cohorts of adults with baseline HIV‐RNA p = 1.000). Additional baseline CD4+ T‐cell percentage adjustment changed the former to −39.8 (−78.5 to −1.2). CD4+ T‐cell percentage differences were + 1.66 and + 1.44 percentage points (both Holm p ≤ 0.002). Original secondary CD8+ T‐cell count differences were − 92.9 and − 96.5 cells/μL (both Holm p = 0.007); the ratio difference versus DTG/3TC was +0.165 (Holm p = 0.013). Conclusions: In these three Spanish cohorts, the primary propensity score‐adjusted analysis did not detect a difference between regimens in the week‐48 CD4+ T‐cell count. Original secondary analyses associated B/F/TAF with lower CD8+ T‐cell counts than both dual regimens and a higher CD4+/CD8+ T‐cell ratio than that of DTG/3TC. The CD8+ T‐cell count and ratio contrasts versus DTG/3TC attenuated after additional baseline percentage adjustment. These associations were sensitive to baseline immune adjustment, and their clinical relevance warrants further investigation.
- 12 November 2026
- Published by Wiley in HIV Medicine
Immune outcomes with dolutegravir‐based dual therapy versus bictegravir‐based triple therapy: A multinomial propensity score analysis
Objectives: To compare immune outcomes after switching to dolutegravir/lamivudine (DTG/3TC), dolutegravir/rilpivirine (DTG/RPV) and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). Methods: Three Spanish cohorts of adults with baseline HIV‐RNA p = 1.000). Additional baseline CD4+ T‐cell percentage adjustment changed the former to −39.8 (−78.5 to −1.2). CD4+ T‐cell percentage differences were + 1.66 and + 1.44 percentage points (both Holm p ≤ 0.002). Original secondary CD8+ T‐cell count differences were − 92.9 and − 96.5 cells/μL (both Holm p = 0.007); the ratio difference versus DTG/3TC was +0.165 (Holm p = 0.013). Conclusions: In these three Spanish cohorts, the primary propensity score‐adjusted analysis did not detect a difference between regimens in the week‐48 CD4+ T‐cell count. Original secondary analyses associated B/F/TAF with lower CD8+ T‐cell counts than both dual regimens and a higher CD4+/CD8+ T‐cell ratio than that of DTG/3TC. The CD8+ T‐cell count and ratio contrasts versus DTG/3TC attenuated after additional baseline percentage adjustment. These associations were sensitive to baseline immune adjustment, and their clinical relevance warrants further investigation.
- Open Access
- 1 January 2024
- Published by Universidad Cientifica del Sur in South Health
- Vol. 1, e003
Assessment of the use and quick preparation of saliva for rapid microbiological diagnosis of COVID-19
- 1 January 2024
- Published by Universidad Cientifica del Sur in South Health
- Vol. 1, e003
Open AccessAssessment of the use and quick preparation of saliva for rapid microbiological diagnosis of COVID-19
- Open Access
Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
Background: The high effectiveness and safety of the two-drug (2DRs) strategy using dolutegravir (DTG) plus lamivudine (3TC) have led to international guidelines recommending their use for treatment-naive HIV patients. In virologically suppressed patients, de-escalating from 3DRs to DTG plus either rilpivirine (RPV) or 3TC has shown high rates of virological suppression. Objectives: This study aimed to compare the real-life data of two multicenter Spanish cohorts of PLWHIV treated with DTG plus 3TC (SPADE-3) or RPV (DORIPEX) as a switch strategy, not only in terms of virological suppression, safety, and durability but also in terms of immune restoration. The primary endpoint was the percentage of patients with virological suppression on DTG plus 3TC and DTG plus RPV at weeks 24 and 48. The secondary outcomes included the proportion of patients who experienced the protocol-defined loss of virological control by week 48; changes in immune status in terms of CD4+ and CD8+ T lymphocyte counts and the CD4+/CD8+ ratio; the rate, incidence, and reasons for discontinuation of treatment over the 48-week study period; and safety profiles at weeks 24 and 48. Methods: We conducted a retrospective, observational, multicenter study of 638 and 943 virologically suppressed HIV-1-infected patients in two cohorts who switched to 2DRs with DTG plus RPV or DTG plus 3TC. Results: The most frequent reasons for starting DTG-based 2DRs were treatment simplification/pill burden or drug decrease. The virological suppression rates were 96.9%, 97.4%, and 99.1% at weeks 24, 48, and 96, respectively. The proportion of patients with virological failure over the 48-week study period was 0.01%. Adverse drug reactions were uncommon. Patients treated with DTG+3TC increased CD4, CD8, and CD4/CD8 parameters at 24 and 48 weeks. Conclusions: We conclude that DTG-based 2DRs (combined with 3TC or RPV) in clinical practice were effective and safe as a switching strategy, with a low VF and high viral suppression rates. Both regimens were well tolerated, and ADR rates were low, including neurotoxicity and induced treatment discontinuations.
Open AccessEfficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
Background: The high effectiveness and safety of the two-drug (2DRs) strategy using dolutegravir (DTG) plus lamivudine (3TC) have led to international guidelines recommending their use for treatment-naive HIV patients. In virologically suppressed patients, de-escalating from 3DRs to DTG plus either rilpivirine (RPV) or 3TC has shown high rates of virological suppression. Objectives: This study aimed to compare the real-life data of two multicenter Spanish cohorts of PLWHIV treated with DTG plus 3TC (SPADE-3) or RPV (DORIPEX) as a switch strategy, not only in terms of virological suppression, safety, and durability but also in terms of immune restoration. The primary endpoint was the percentage of patients with virological suppression on DTG plus 3TC and DTG plus RPV at weeks 24 and 48. The secondary outcomes included the proportion of patients who experienced the protocol-defined loss of virological control by week 48; changes in immune status in terms of CD4+ and CD8+ T lymphocyte counts and the CD4+/CD8+ ratio; the rate, incidence, and reasons for discontinuation of treatment over the 48-week study period; and safety profiles at weeks 24 and 48. Methods: We conducted a retrospective, observational, multicenter study of 638 and 943 virologically suppressed HIV-1-infected patients in two cohorts who switched to 2DRs with DTG plus RPV or DTG plus 3TC. Results: The most frequent reasons for starting DTG-based 2DRs were treatment simplification/pill burden or drug decrease. The virological suppression rates were 96.9%, 97.4%, and 99.1% at weeks 24, 48, and 96, respectively. The proportion of patients with virological failure over the 48-week study period was 0.01%. Adverse drug reactions were uncommon. Patients treated with DTG+3TC increased CD4, CD8, and CD4/CD8 parameters at 24 and 48 weeks. Conclusions: We conclude that DTG-based 2DRs (combined with 3TC or RPV) in clinical practice were effective and safe as a switching strategy, with a low VF and high viral suppression rates. Both regimens were well tolerated, and ADR rates were low, including neurotoxicity and induced treatment discontinuations.
- Open Access
Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to DTG+3TC from 13 Spanish hospitals. DTG+3TC provided high rates of undetectable viral load over 96%, corresponding to 96.6% (889/921) at 24 weeks, 97.5% (743/763) at 48 weeks, and 98.3% (417/425) at 96 weeks. No significant differences are evident when comparing the total population according to sex, presence of comorbidity, or presence of AIDS. The analysis for paired data showed an increase in CD4+ cell count. A statistically significant increase in CD4+ lymphocyte count was found in those without comorbidities in the three-time series analyzed [average increase at 24 weeks: 48.7 (SD: 215.3) vs. 25.8 (SD: 215.5), p-value = 0.050; a mean increase at 48 weeks: 75.1 (SD: 232.9) vs. 42.3 (SD: 255.6), p-value = 0.003; a mean increase at 96 weeks: 120.1 (SD: 205.0) vs. 63.8 (SD:275.3), p-value = 0.003]. In conclusion, our cohort demonstrates that DTG+3TC is an effective treatment strategy for virologically-suppressed PLWHIV independent of age, sex, and HIV stage, as well as a safe and durable strategy.
Open AccessDolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to DTG+3TC from 13 Spanish hospitals. DTG+3TC provided high rates of undetectable viral load over 96%, corresponding to 96.6% (889/921) at 24 weeks, 97.5% (743/763) at 48 weeks, and 98.3% (417/425) at 96 weeks. No significant differences are evident when comparing the total population according to sex, presence of comorbidity, or presence of AIDS. The analysis for paired data showed an increase in CD4+ cell count. A statistically significant increase in CD4+ lymphocyte count was found in those without comorbidities in the three-time series analyzed [average increase at 24 weeks: 48.7 (SD: 215.3) vs. 25.8 (SD: 215.5), p-value = 0.050; a mean increase at 48 weeks: 75.1 (SD: 232.9) vs. 42.3 (SD: 255.6), p-value = 0.003; a mean increase at 96 weeks: 120.1 (SD: 205.0) vs. 63.8 (SD:275.3), p-value = 0.003]. In conclusion, our cohort demonstrates that DTG+3TC is an effective treatment strategy for virologically-suppressed PLWHIV independent of age, sex, and HIV stage, as well as a safe and durable strategy.
- Open Access
- 17 June 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (24) , e29252
Dolutegravir plus rilpivirine: benefits beyond viral suppression
Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the basis of clinical practice data. A multicentric retrospective cohort study. Treatment-experienced virologically suppressed HIV-1-infected patients who were switched to DTG plus RPV were included. Using different models for paired data, we evaluated the efficacy and immune status in terms of CD4+ and CD8+ T-cell counts and CD4/CD8 ratio at 24 and 48 weeks of treatment. The study population comprised of 524 patients from 34 centers in Spain. Men accounted for 76.9% of patients, with a median age of 53 years. Patients receiving DTG plus RPV reached weeks 24 and 48 in 99.4% and 83.8% of cases, respectively, with only three (0.57%) virological failures. We found a significant decrease in CD8+ T-cell count (log OR –40) at week 24 and an increase in CD4+ T-cell count at week 48 (log OR +22.8). In acquired immunodeficiency syndrome-diagnosed patients, we found a significant increase in the CD4+ T-cell count at week 48 (log OR = 41.7, P = .0038), but no significant changes in the CD8+ T-cell count (log OR = –23.4, P = .54). No differences were found in the CD4/CD8 ratio between the acquired immunodeficiency syndrome subgroup and sex or age. In patients with controlled treatment, dual therapy with DTG plus RPV slightly improved the immune status during the first 48 weeks after switching, not only in terms of CD4+ T-cell count but also in terms of CD8+ T-cell count, with persistently high rates of viral control.
- 17 June 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (24) , e29252
Open AccessDolutegravir plus rilpivirine: benefits beyond viral suppression
Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the basis of clinical practice data. A multicentric retrospective cohort study. Treatment-experienced virologically suppressed HIV-1-infected patients who were switched to DTG plus RPV were included. Using different models for paired data, we evaluated the efficacy and immune status in terms of CD4+ and CD8+ T-cell counts and CD4/CD8 ratio at 24 and 48 weeks of treatment. The study population comprised of 524 patients from 34 centers in Spain. Men accounted for 76.9% of patients, with a median age of 53 years. Patients receiving DTG plus RPV reached weeks 24 and 48 in 99.4% and 83.8% of cases, respectively, with only three (0.57%) virological failures. We found a significant decrease in CD8+ T-cell count (log OR –40) at week 24 and an increase in CD4+ T-cell count at week 48 (log OR +22.8). In acquired immunodeficiency syndrome-diagnosed patients, we found a significant increase in the CD4+ T-cell count at week 48 (log OR = 41.7, P = .0038), but no significant changes in the CD8+ T-cell count (log OR = –23.4, P = .54). No differences were found in the CD4/CD8 ratio between the acquired immunodeficiency syndrome subgroup and sex or age. In patients with controlled treatment, dual therapy with DTG plus RPV slightly improved the immune status during the first 48 weeks after switching, not only in terms of CD4+ T-cell count but also in terms of CD8+ T-cell count, with persistently high rates of viral control.
- Open Access
- 30 January 2022
- Published by Edicions de la Universitat de Barcelona in MUSAS. Revista de Investigación en Mujer, Salud y Sociedad
- Vol. 7 (1) , 130-150
Valoración de la calidad de atención a pacientes que solicitan interrupción tardía de la gestación
Objetivo. Evaluar la experiencia de las pacientes en proceso de interrupción voluntaria del embarazo por malformaciones fetales graves o incurables por encima de las 22 semanas de gestación. Material y métodos. Se realizó un estudio piloto descriptivo de corte transversal empleando un cuestionario ad hoc con 15 preguntas relacionadas con la calidad de atención y el proceso de pérdida gestacional desarrolladas por un equipo multidisciplinar del Hospital Clínic de Barcelona. La calidad de la atención se evaluó mediante una puntuación de 0 a 10 puntos. Resultados. La puntuación global de la atención prestada fue de 9,45. El ruido ambiental en las diferentes instalaciones hospitalarias fue puntuado con un 5,98/10 y el tiempo desde el parto hasta el alta obtuvieron una puntuación de 6,22. A todas las pacientes se les ofreció contacto con su bebé, pero al 58 % de las familias les hubiera gustado recibir además de las huellas otros recuerdos y al 47 % hubiera deseado hacer fotografías a su bebé. Además, el 37 % de las familias dijeron que hubiesen pasado más tiempo con su bebé. Finalmente, el 53 % de las familias refirió la necesidad de requerir apoyo psicológico o suporte emocional, tanto durante el ingreso hospitalario como en el puerperio. Conclusión. La valoración general de la atención prestada fue adecuada, aunque algunos aspectos podrían mejorarse. La realización de una encuesta a las familias sometidas a un IVE tardío es un método útil para evaluar la calidad de la atención brindada y diseñar acciones de mejora.
- 30 January 2022
- Published by Edicions de la Universitat de Barcelona in MUSAS. Revista de Investigación en Mujer, Salud y Sociedad
- Vol. 7 (1) , 130-150
Open AccessValoración de la calidad de atención a pacientes que solicitan interrupción tardía de la gestación
Objetivo. Evaluar la experiencia de las pacientes en proceso de interrupción voluntaria del embarazo por malformaciones fetales graves o incurables por encima de las 22 semanas de gestación. Material y métodos. Se realizó un estudio piloto descriptivo de corte transversal empleando un cuestionario ad hoc con 15 preguntas relacionadas con la calidad de atención y el proceso de pérdida gestacional desarrolladas por un equipo multidisciplinar del Hospital Clínic de Barcelona. La calidad de la atención se evaluó mediante una puntuación de 0 a 10 puntos. Resultados. La puntuación global de la atención prestada fue de 9,45. El ruido ambiental en las diferentes instalaciones hospitalarias fue puntuado con un 5,98/10 y el tiempo desde el parto hasta el alta obtuvieron una puntuación de 6,22. A todas las pacientes se les ofreció contacto con su bebé, pero al 58 % de las familias les hubiera gustado recibir además de las huellas otros recuerdos y al 47 % hubiera deseado hacer fotografías a su bebé. Además, el 37 % de las familias dijeron que hubiesen pasado más tiempo con su bebé. Finalmente, el 53 % de las familias refirió la necesidad de requerir apoyo psicológico o suporte emocional, tanto durante el ingreso hospitalario como en el puerperio. Conclusión. La valoración general de la atención prestada fue adecuada, aunque algunos aspectos podrían mejorarse. La realización de una encuesta a las familias sometidas a un IVE tardío es un método útil para evaluar la calidad de la atención brindada y diseñar acciones de mejora.
- Open Access
Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study
Importance Identifying undetected clinical signs is imperative in the prevention of SARS-CoV-2. Objective To establish the prevalence of clinical gustatory and olfactory dysfunctions in patients with COVID-19 pneumonia. Clinical outcomes and recovery rates associated with gustatory and olfactory dysfunctions were also assessed. Design A prospective study was performed in 80 patients admitted to Hospital Clínic of Barcelona (Spain) for COVID-19 pneumonia. Patients were re-evaluated in the ward daily until discharge. Gustatory and olfactory dysfunction symptoms were retrospectively collected from emergency room (ER) charts after first assessments. Follow-up was performed in telemedicine consultation. Setting The single-centre study was performed in a hospitalisation ward at a university hospital. Participants Consecutive patients meeting hospitalisation criteria for COVID-19 pneumonia were eligible. Study exclusion criteria were patients who could not speak, had previous gustatory and olfactory dysfunctions or whose PCR tests for SARS-CoV-19 were negative. Interventions Systematic assessment of gustatory and olfactory symptoms with standardised questions. Outcome(s) Prevalence of gustatory and olfactory dysfunctions in patients with COVID-19 pneumonia. Results Of the 80 study subjects, 62.5% were male and the median age was 57 years. Half of the cohort (n=40) presented with comorbidities. The prevalence of chemosensitive disorder was 73.8% (n=59) (95% CI: 63.8 to 83.8), although self-reported symptoms were recorded in only 26.3% (n=21) of patients in the ER. Gustatory and olfactory dysfunctions were observed in 58.8% (n=47) and 55% (n=44) of cases, respectively. They were also the first symptoms in 25% (n=20) of patients. Anosmia was associated with ageusia, OR: 7, 95% CI: 2.3 to 21.8, p=0.001). No differences in clinical outcomes were observed when patients with and without gustatory and olfactory dysfunctions were compared. Recovery rates were 20% (n=10) and 85% (n=42) at days 7 and 45, respectively. Conclusion The prevalence of gustatory and olfactory dysfunctions in COVID-19 pneumonia was much higher than in self-report. Presence of gustatory and olfactory dysfunctions was not a predictor of clinical outcomes.
Open AccessGustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study
Importance Identifying undetected clinical signs is imperative in the prevention of SARS-CoV-2. Objective To establish the prevalence of clinical gustatory and olfactory dysfunctions in patients with COVID-19 pneumonia. Clinical outcomes and recovery rates associated with gustatory and olfactory dysfunctions were also assessed. Design A prospective study was performed in 80 patients admitted to Hospital Clínic of Barcelona (Spain) for COVID-19 pneumonia. Patients were re-evaluated in the ward daily until discharge. Gustatory and olfactory dysfunction symptoms were retrospectively collected from emergency room (ER) charts after first assessments. Follow-up was performed in telemedicine consultation. Setting The single-centre study was performed in a hospitalisation ward at a university hospital. Participants Consecutive patients meeting hospitalisation criteria for COVID-19 pneumonia were eligible. Study exclusion criteria were patients who could not speak, had previous gustatory and olfactory dysfunctions or whose PCR tests for SARS-CoV-19 were negative. Interventions Systematic assessment of gustatory and olfactory symptoms with standardised questions. Outcome(s) Prevalence of gustatory and olfactory dysfunctions in patients with COVID-19 pneumonia. Results Of the 80 study subjects, 62.5% were male and the median age was 57 years. Half of the cohort (n=40) presented with comorbidities. The prevalence of chemosensitive disorder was 73.8% (n=59) (95% CI: 63.8 to 83.8), although self-reported symptoms were recorded in only 26.3% (n=21) of patients in the ER. Gustatory and olfactory dysfunctions were observed in 58.8% (n=47) and 55% (n=44) of cases, respectively. They were also the first symptoms in 25% (n=20) of patients. Anosmia was associated with ageusia, OR: 7, 95% CI: 2.3 to 21.8, p=0.001). No differences in clinical outcomes were observed when patients with and without gustatory and olfactory dysfunctions were compared. Recovery rates were 20% (n=10) and 85% (n=42) at days 7 and 45, respectively. Conclusion The prevalence of gustatory and olfactory dysfunctions in COVID-19 pneumonia was much higher than in self-report. Presence of gustatory and olfactory dysfunctions was not a predictor of clinical outcomes.
- Open Access
- 30 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0251010
Changing epidemiology of catheter-related bloodstream infections in neutropenic oncohematological patients
Background: We aimed to describe the epidemiology of catheter-related bloodstream infections (CRBSIs) in onco-hematological neutropenic patients during a 25-year study period, to evaluate the risk factors for Gram-negative bacilli (GNB) CRBSI, as well as rates of inappropriate empirical antibiotic treatments (IEAT) and mortality. Materials/Methods: All consecutive episodes of CRBSIs were prospectively collected (1994–2018). Changing epidemiology was evaluated comparing five-year time spans. A multivariate regression model was built to evaluate risk factors for GNB CRBSIs. Results: 482 monomicrobial CRBSIs were documented. The proportion of CRBSIs among all BSIs decreased over time from 41.2% to 15.8% (pP. aeruginosa increased and comprised up to 40% of all GNB. Independent factors related with GNB-CRBSIs were: longer duration of in-situ catheter (OR 1.007; 95%CI 1.004–1.011), older age (OR 1.016; 95%CI 1.001–1.033), prior antibiotic treatment with penicillins (OR 2.716; 95%CI 1.306–5.403), and current antibiotic treatment with glycopeptides (OR 1.931; 95%CI 1.001–3.306). IEATs were administered to 30.7% of patients, with the highest percentage among MDR P. aeruginosa (76.9%) and S. maltophillia (92.9%). Mortality rate was greater among GNB than GPC-CRBSI (14.4% vs 5.4%; p = 0.002), with mortality increasing over time (from 4.5% to 11.2%; p = 0.003). Conclusion: A significant shift towards GNB-CRBSIs was observed. Secondarily, and coinciding with an increasing number of GNB-MDR infections, mortality increased over time.
- 30 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0251010
Open AccessChanging epidemiology of catheter-related bloodstream infections in neutropenic oncohematological patients
Background: We aimed to describe the epidemiology of catheter-related bloodstream infections (CRBSIs) in onco-hematological neutropenic patients during a 25-year study period, to evaluate the risk factors for Gram-negative bacilli (GNB) CRBSI, as well as rates of inappropriate empirical antibiotic treatments (IEAT) and mortality. Materials/Methods: All consecutive episodes of CRBSIs were prospectively collected (1994–2018). Changing epidemiology was evaluated comparing five-year time spans. A multivariate regression model was built to evaluate risk factors for GNB CRBSIs. Results: 482 monomicrobial CRBSIs were documented. The proportion of CRBSIs among all BSIs decreased over time from 41.2% to 15.8% (pP. aeruginosa increased and comprised up to 40% of all GNB. Independent factors related with GNB-CRBSIs were: longer duration of in-situ catheter (OR 1.007; 95%CI 1.004–1.011), older age (OR 1.016; 95%CI 1.001–1.033), prior antibiotic treatment with penicillins (OR 2.716; 95%CI 1.306–5.403), and current antibiotic treatment with glycopeptides (OR 1.931; 95%CI 1.001–3.306). IEATs were administered to 30.7% of patients, with the highest percentage among MDR P. aeruginosa (76.9%) and S. maltophillia (92.9%). Mortality rate was greater among GNB than GPC-CRBSI (14.4% vs 5.4%; p = 0.002), with mortality increasing over time (from 4.5% to 11.2%; p = 0.003). Conclusion: A significant shift towards GNB-CRBSIs was observed. Secondarily, and coinciding with an increasing number of GNB-MDR infections, mortality increased over time.
- Open Access
Assessment of the use and quick preparation of saliva for rapid microbiological diagnosis of COVID-19
The objective of this study was to assess the performance of direct real time RT-PCR detection of SARS-CoV-2 in heated saliva samples, avoiding the RNA isolation step. Oropharyngeal and nasopharyngeal swabs together with saliva samples were obtained from 51 patients clinically diagnosed as potentially having COVID-19. Two different methods were compared: 1. RNA was extracted from 500 μl of sample using a MagNA Pure Compact Instrument with an elution volume of 50μl and 2. 700µL of saliva were heat-inactivated at 96°C for 15 minutes, and directly subjected to RT-PCR. One step real time RT-PCR was performed using 5 μl of extracted RNA or directly from 5 μl of heated sample. RT-PCR was performed targeting the SARS-CoV-2 envelope (E) gene region. Diagnostic performance was assessed using the results of the RT-PCR from nasopharyngeal and oropharyngeal swabs as the gold standard. The overall sensitivity, specificity, positive and negative predictive values were 81.08%, 92.86%, 96.77% and 65.00%, respectively when RNA extraction was included in the protocol with saliva, whereas sensitivity, specificity, positive and negative predictive values were 83.78%, 92.86%, 68.42% and 96.88%, respectively, for the heat-inactivation protocol. However, when the analysis was performed exclusively on saliva samples with a limited time from the onset of symptoms (<9 days, N=28), these values were 90%, 87.5%, 44% and 98.75% for the heat-inactivation protocol. The study showed that RT-PCR can be performed using saliva in an RNA extraction free protocol, showing good sensitivity and specificity.
Open AccessAssessment of the use and quick preparation of saliva for rapid microbiological diagnosis of COVID-19
The objective of this study was to assess the performance of direct real time RT-PCR detection of SARS-CoV-2 in heated saliva samples, avoiding the RNA isolation step. Oropharyngeal and nasopharyngeal swabs together with saliva samples were obtained from 51 patients clinically diagnosed as potentially having COVID-19. Two different methods were compared: 1. RNA was extracted from 500 μl of sample using a MagNA Pure Compact Instrument with an elution volume of 50μl and 2. 700µL of saliva were heat-inactivated at 96°C for 15 minutes, and directly subjected to RT-PCR. One step real time RT-PCR was performed using 5 μl of extracted RNA or directly from 5 μl of heated sample. RT-PCR was performed targeting the SARS-CoV-2 envelope (E) gene region. Diagnostic performance was assessed using the results of the RT-PCR from nasopharyngeal and oropharyngeal swabs as the gold standard. The overall sensitivity, specificity, positive and negative predictive values were 81.08%, 92.86%, 96.77% and 65.00%, respectively when RNA extraction was included in the protocol with saliva, whereas sensitivity, specificity, positive and negative predictive values were 83.78%, 92.86%, 68.42% and 96.88%, respectively, for the heat-inactivation protocol. However, when the analysis was performed exclusively on saliva samples with a limited time from the onset of symptoms (<9 days, N=28), these values were 90%, 87.5%, 44% and 98.75% for the heat-inactivation protocol. The study showed that RT-PCR can be performed using saliva in an RNA extraction free protocol, showing good sensitivity and specificity.
- 1 March 2020
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 26 (3) , 345-350
Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection
- 1 March 2020
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 26 (3) , 345-350
Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection